Please login to the form below
facioscapulohumeral muscular dystrophy
This page shows the latest facioscapulohumeral muscular dystrophy news and features for those working in and with pharma, biotech and healthcare.
SOLVE FSHD announces the appointment of Dr Eva Chin as its executive director
The company is focused on finding a cure for facioscapulohumeral muscular dystrophy. ... It was also shared that Chip Wilson, founder of SOLVE FSHD, has committed a personal pledge of $100m towards a cure for facioscapulohumeral muscular dystrophy (FSHD),
Latest news
-
Acceleron rockets on positive mid-stage pulmonary arterial hypertension data
Despite the drug hitting its primary endpoint in a phase 2 facioscapulohumeral muscular dystrophy (FSHD) trial, Acceleron took the decision to pull ACE-083 after a sift through the secondary endpoint
-
Acceleron scraps rare muscular dystrophy drug
Clinical profile not strong enough to push into late-stage testing. Acceleron has abandoned a drug for facioscapulohumeral muscular dystrophy (FSHD), even though it hit the mark on the primary endpoint
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
foxandcat.online
We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
